ClearPoint Neuro (CLPT): Can the Stock Climb Back to $25?

Key Takeaways

• The selected price target is $25, roughly 60% above recent trading levels near $15 and below the stock's 52-week high of $30.10.
• Wall Street consensus is a Strong Buy, with analyst price targets ranging from $22 to $30 and averages clustered near $23.50 to $25.
• The strongest bullish catalysts are expanding biopharma partnerships, notably uniQure's (QURE) Huntington's disease program and Aspen Neuroscience's Parkinson's cell therapy.
• Key obstacles include persistent net losses, negative cash flow, a recent revenue guidance cut, and elevated short interest.
• Reaching $25 likely depends on revenue reacceleration and tangible progress from gene therapy partners rather than valuation expansion alone.

Company Snapshot

ClearPoint Neuro develops and commercializes the ClearPoint system, which allows surgeons to conduct minimally invasive brain procedures under direct MRI guidance during the operation. The platform consists of hardware like a head-fixation frame and workstation, plus disposables such as the SmartFrame trajectory device and SmartFlow cannula. In recent years the company has focused more on supporting neuro cell and gene therapy delivery for a network of over 60 biopharma partners.

Current Trading Position

CLPT trades near $15, for a market capitalization of roughly $467 million. Over the past year the shares have moved sharply, from a low of $8.27 to a high of $30.10, with a beta around 1.27. Trailing twelve-month revenue came in near $42 million, more than 25% higher year over year, yet the company posted a net loss of about $34.6 million. Cash stands at roughly $29 million against $64 million in debt. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The Appeal of the $25 Level

The $25 mark aligns closely with published analyst targets. Lake Street Capital keeps a Buy rating and $25 objective, B. Riley Securities lists $30, and Stifel carries $22. The consensus average sits near $23.50 to $25, so $25 represents a logical round-number goal that reflects mainstream expectations over the next twelve months. Importantly, it is not arbitrary—the stock already traded through that level during last year’s rally toward $30.

Potential Drivers Higher

Progress among gene therapy partners remains the clearest catalyst. In mid-2026 shares rose about 32% after uniQure outlined plans for a biologics license application submission for AMT-130 in Huntington’s disease, a move B. Riley referenced when lifting its target from $20 to $30. Separately, partner Aspen Neuroscience earned Regenerative Medicine Advanced Therapy designation from the FDA for its Parkinson’s cell therapy, which could speed review. ClearPoint’s navigation and delivery tools are used in these procedures, so successful commercial adoption by partners could generate more stable, procedure-based revenue.

The company continues to expand its technology reach. It obtained CE Marking for the Velocity Alpha MR high-speed surgical drill system and entered a ten-year focused ultrasound development partnership with Sungkyunkwan University in South Korea. The IRRAS acquisition added the IRRAflow product to the neurosurgery lineup.

Obstacles That Remain

The route to $25 faces several hurdles. ClearPoint stays deeply unprofitable, with negative operating cash flow and ongoing cash burn. Management recently trimmed full-year 2026 revenue guidance to $48 million–$52 million from the prior $52 million–$56 million range, pointing to a focus on higher-return investments. Second-quarter 2026 revenue of about $10.9 million also fell short of consensus estimates.

Sentiment shows caution too. Short interest stands at roughly 14% of shares outstanding, and recent insider activity has tilted toward selling. With no earnings and a price-to-sales ratio above 10, the valuation rests heavily on growth that has yet to fully appear.

Technical Levels Worth Watching

From a technical standpoint, the $15 zone has served as a key battleground, while the prior $30 high sets the main upside reference. In between, $20 and $25 act as psychological markers, with $25 as the primary recovery objective in the near-to-intermediate term. A sustained move above the mid-teens would mark the first step toward rebuilding momentum, while the $8–$9 area remains the lower bound of the range and a meaningful support level.

Enhancing Research with AI Signals

I regularly turn to Tickeron’s AI Daily Buy/Sell Signals when reviewing names like CLPT. The tool scans thousands of stocks and ETFs daily, applying artificial intelligence to technical patterns and market shifts to produce Buy, Sell, or Hold signals. It helps me identify potential entry points and monitor trend changes alongside fundamental work, adding a systematic element to the overall process.

Final Assessment

Moving from current levels to $25 looks plausible yet far from assured. The case rests on analyst support and a pipeline of gene therapy partnerships that could eventually deliver recurring procedure revenue. Counterbalancing factors include ongoing losses, the recent guidance reduction, and a valuation that already prices in substantial future growth. For the target to become realistic, revenue would need to reaccelerate, key partners would need clearer timelines, and the cash position would need to stabilize. Until those elements align, $25 remains an achievable benchmark on paper that ultimately depends on execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume